Investors

Physiomics is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company uses a combination of industry standard and its own proprietary Virtual Tumour modelling technologies to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 70 projects, involving over 25 targets and 60 drugs.

Please use the links below to access information for investors as required under AIM rule 26 (last updated 3rd June 2019).

Share Information

Read more

Investor News

Read more

Board of Directors

Read more

Advisors

Read more

Corporate Governance

Read more

Reports & Prospectus

Read more
})(jQuery)